HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy

scientific article

HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/MD.0000000000004809
P932PMC publication ID5402576
P698PubMed publication ID27631233

P50authorXue LiQ57554800
P2093author name stringZhihong Liu
Jiong Zhang
Jinsong Chen
Dongrui Cheng
Jiqiu Wen
Mingchao Zhang
Shuming Ji
Kenan Xie
P2860cites workRenal allograft rejection associated with presensitization to HLA-DR antigensQ72635105
Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy studyQ81180642
De novo membranous nephropathy and antibody-mediated rejection in transplanted kidneyQ83199466
PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathyQ83416838
C4d deposition and multilayering of peritubular capillary basement membrane in posttransplantation membranous nephropathy indicate its association with antibody-mediated injuryQ83828722
Human idiopathic membranous nephropathy--a mystery solved?Q84155266
Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathyQ84728773
Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodiesQ84758630
PLA2R Autoantibodies and Recurrent Membranous Nephropathy after TransplantationQ84984695
Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathyQ86439847
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathyQ24652978
Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative studyQ28141871
Posttransplantation relapse of FSGS is characterized by glomerular epithelial cell transdifferentiationQ30649838
Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantationQ33827375
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathyQ34783516
Anti-phospholipase A2 receptor antibody in membranous nephropathyQ35012441
Membranous nephropathy: recent travels and new roads aheadQ37698191
De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease?Q38036393
Clinical and experimental aspects of renal allograft rejectionQ40324995
HLA-DR overexpression in tubules of renal allografts during early and late renal allograft injuriesQ42248630
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesionsQ45342440
Secondary membranous nephropathy--one center experienceQ46628913
What is the significance of HLA-DR antigen expression in the extraglomerular mesangium in glomerulonephritis?Q51318200
Expression of HLA-DR, -DQ, and -DP antigens on renal tubular cells during rejection episodesQ68868870
Diagnosis of renal allograft rejection by analysis of fine-needle aspiration biopsy specimens with immunostains and simple cytologyQ69887398
Expression of HLA-DR antigens on peripheral blood T lymphocytes and renal graft tubular epithelial cells in association with rejectionQ70155771
Induction of MHC class II molecules HLA-DR, -DP and -DQ and ICAM 1 in human podocytes by gamma-interferonQ72387795
Increased expression of HLA-DR antigens on renal tubular cells in renal transplants: relevance to the rejection responseQ72584726
P433issue37
P407language of work or nameEnglishQ1860
P304page(s)e4809
P577publication date2016-09-01
P1433published inMedicineQ15716652
P1476titleHLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy
P478volume95

Search more.